Clinical Trials Logo

Eosinophilic Esophagitis (EoE) clinical trials

View clinical trials related to Eosinophilic Esophagitis (EoE).

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06389994 Recruiting - Clinical trials for Eosinophilic Esophagitis (EoE)

Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy

Start date: April 1, 2024
Phase:
Study type: Observational

Patients with IgE mediated food Allergy have elevated risk of eosinophilic esophagitis, and new therapies like oral immunotherapy (OIT) carry additional risk of Eosinophilic Esophagitis (EoE). The goal of this study is to investigate the Esophageal String Test (EST) as a screening tool for Eosinophilic Esophagitis (EoE) during OIT therapy. Investigators will compare the efficacy of the Esophageal String Test to symptom assessment using a validated patient reported symptom questionnaire, the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) v2.0. Investigators will utilize these tools to screen patients at their baseline visit prior to the start of OIT, then at the 3- and 6-month OIT follow-up visits.

NCT ID: NCT04626609 Recruiting - Clinical trials for Eosinophilic Esophagitis (EoE)

Prostaglandin and Cannabinoid Receptors in EoE

Start date: July 1, 2021
Phase:
Study type: Observational

The purpose of this study is to investigate prostaglandin and cannabinoid receptors and their endogenous ligands in eosinophilic esophagitis (EoE). A prostaglandin D2 receptor antagonist has been shown to improve disease symptoms suggesting a regulatory role for bioactive lipids in EoE. Prostaglandin D2 and E2, and endocannabinoids are lipid mediators that govern the functional and inflammatory behavior of immune cells critical for EoE development. The prostaglandin D2 and E2 receptor axis, and the components of the endocannabinoid may be involved in the pathogenesis of EoE.